Nanda R N, Arthur G P, Johnson R H, Lambie D G
Acta Neurol Scand. 1980 Aug;62(2):90-5. doi: 10.1111/j.1600-0404.1980.tb03008.x.
The prophylactic effect of the histamine H2-blocker cimetidine, either alone or combined with an H1-blocker (chlorpheniramine), was investigated in 34 migraine patients in a double-blind crossover trial. Twelve patients withdrew during the course of the trial, one because of the side effects and the remainder because of failure to attend checkups or to keep adequate record of attacks. In the 22 patients who completed the trial, there were no significant responses to cimetidine or cimetidine + chlorpheniramine, during 3 months' therapy, as compared with 3 months' therapy with placebo, either on number, duration or severity of attacks. The study demonstrates that cimetidine is unlikely to be effective in migraine, and casts doubt on the role of histamine in the development of migraine attacks.
在一项双盲交叉试验中,对34名偏头痛患者研究了组胺H2受体阻滞剂西咪替丁单独使用或与H1受体阻滞剂(氯苯那敏)联合使用的预防效果。12名患者在试验过程中退出,1名因副作用退出,其余因未参加检查或未充分记录发作情况而退出。在完成试验的22名患者中,与使用安慰剂进行3个月治疗相比,在接受西咪替丁或西咪替丁+氯苯那敏治疗的3个月期间,发作的次数、持续时间或严重程度均无显著反应。该研究表明,西咪替丁不太可能对偏头痛有效,并对组胺在偏头痛发作发展中的作用提出了质疑。